Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase I/II study of the combination of etanercept and rituximab in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This combination is proposed to improve the efficacy and diminish the toxicity of this the

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: John Byrd; Ohio State University Comprehensive Cancer Center
• Treatments: Etanercept; Rituximab

Criteria

Inclusion Criteria:

• Must have been previously treated CLL/SLL

• Must have CD20 expression

• ECOG PS =<3

• No prior Campath-1H

• No active infection requiring antibiotics

• No concurrent immunosuppressive therapy

• No prior history demyelinating neurologic disease

• No active viral hepatitis

Exclusion Criteria:

• No pregnant or breastfeeding women

• ECOG PS =4

• Life expectancy of >12 weeks

• Patients with bilirubin or creatinine>3.0 mg/dl